Staphylococcus aureus is a Gram-positive toxin-forming bacterium that is a widespread human commensal and pathogen.
Approximately 30-60% of the population is colonized either permanently or intermittently.
S.aureus (SA) is responsible for a wide range of clinical syndromes ranging from high mortality blood stream infections (BSIs) to community-based skin and soft tissue infections such as skin abscesses (SSTIs).
SA is a common cause of healthcare-associated infections (HAIs) such as pneumonia and surgical site infections (SSIs).
An antibiotic resistant form of S.aureus (MRSA) has become a major problem both in and out of the hospital with an estimated ~88-90K infections occurring in the USA each year with substantial economic burden.
SA vaccines which prevent and/or reduce the impact of SA infections are greatly needed although it is becoming accepted that a universal vaccine to impact upon all infection types and reduce colonization is an optimistic goal.
Pfizer vaccines is developing SA4Ag, a multicomponent vaccine (Phase IIb, fast track designation) to address SA BSI and SSIs in surgical patients undergoing elective open posterior spinal fusion procedures. The company
has recently asked the FDA VRBAC committee to consider conversion of its current study to a Phase III (n=6000) for orthpedic surgery patients.
This MarketVIEW product consists of a detailed Executive presentation (~155 .pdf slides) and comprehensive MS-Excel work book (.xls) which forecast the potential commercial value of a S.aureus “healthcare-associated” vaccine to target BSIs and SSIs in US surgical and
End-stage renal disease patients (ESRD) in the US to 2030. For surgery patients (12 types), there is a sophisticated uptake methodology whereby certain surgical procedures are assigned a priority level along with an assessment of US state (group of) HO-MRSA risk.
Efforts have been made to account for complex overlapping datasets so that discrete numbers of procedures can be forecast as vaccine eligible populations. The analysis also provides a detailed review of latest S.aureus (MRSA) US epidemiology (EIP, NHSN), prevention/legislative efforts (HHS Action Plan), vaccinology and current R&D approaches/activity.
MarketVIEW: Staphylococcus aureus BSI/SSI vaccine (USA) lays a firm groundwork designed to initiate or challenge any internal client assessment of this exciting but challenging commercial opportunity.
THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 170 slides) + 1 MODEL (.xls, 55 worksheets)